Integra Lifesciences Holdings (IART) Change in Accured Expenses (2009 - 2026)

Integra Lifesciences Holdings (IART) has 18 years of Change in Accured Expenses data on file, last reported at -$19.2 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses fell 6.59% year-over-year to -$19.2 million; the trailing twelve-month figure through Mar 2026 stood at $25.5 million (up 1844.4% YoY), and the FY2025 full-year result was $26.7 million, up 1099.4% from the prior year.
• Change in Accured Expenses declined to -$19.2 million in Q1 2026, from $23.0 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $23.0 million in Q4 2025 to a low of -$19.2 million in Q1 2024.
• A 5-year average of $116352.9 and a median of -$4.8 million in 2022 frame the typical range for Change in Accured Expenses.
• Across the five-year window, Change in Accured Expenses soared 1944.11% in 2022 and plunged 380.33% in 2024, its largest moves.
• Tracing IART's Change in Accured Expenses over 5 years: stood at $18.1 million in 2022, then plunged by 89.46% to $1.9 million in 2023, then tumbled by 380.33% to -$5.4 million in 2024, then jumped by 529.48% to $23.0 million in 2025, then plunged by 183.34% to -$19.2 million in 2026.
• Business Quant data shows IART's Change in Accured Expenses at -$19.2 million in Q1 2026, $23.0 million in Q4 2025, and $5.8 million in Q3 2025.